Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase [1] used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects. It is structurally related to the antiarrhythmic amiodarone. [2]

苯溴马隆是一种有机物，化学式为C17H12O3Br2，为白色至灰白色结晶粉末。 苯溴马隆是一种 苯并呋喃 中的具有 代表性 的衍生物，具有强力去尿酸的作用，还可以有效地抑制尿酸的生成，对降低 血尿酸 的浓度具有 双重作用，缓解疼痛和 红肿，消除 痛风结石，可用于治疗 原发性 高尿酸血症， 痛风性关节炎 间歇期及痛风结节肿等。 抗痛风药。 [3-6] 原发性高尿酸血症，以及 痛风性关节炎 间歇期。 1、对本品中任何成分过敏者。 2、中至重度肾效用侵害者（肾小球滤过率 低 …

2019年8月7日 · Benzbromarone is a uricosuric drug that has been used in the treatment of gout over the last 30 years. Due to its potent inhibition of the dominant apical (luminal) urate exchanger in the human proximal tubule URAT1, it reduces the urate reabsorption, diminishing serum urate levels and therefore preventing gout flares.

benzbromarone的用量、作用機轉、副作用、懷孕及哺乳用藥與藥物交互作用，benzbromarone適應症:痛風、高尿酸血症。

2016年10月20日 · Benzbromarone is a uricosuric agent which is taken daily for the prevention of gout flares. Benzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.

英文名称：Benzbromarone tablets 汉语拼音：Benxiumalong Pian 【成份】 本品主要成份是苯溴马隆。 【性状】 本品为白色或类白色片。 【适应症】 原发性高尿酸血症，痛风性关节炎间歇期及痛风结节肿等。 【用法用量】

Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects. In open short- and long-term studies benzbromarone reduced serum uric acid levels by one-third to one-half and maintained its effectiveness for perio …

药理作用：本品属苯骈呋喃衍生物，为促尿酸排泄药，作用机制主要定通过抑制肾小管对尿酸的重吸收，从而降低血中尿酸浓度。 毒理研究：据报道，大鼠长期口服 [50mg/kg/日 (约为临床用 …

Benzbromarone is an orally active anti-gout agent. Benzbromarone has anti-infammatory, anti-oxidative stress and nephroprotective effects. Benzbromarone can be used for the research of hyperuricemia and gout.

Urate-lowering therapies aim to prevent gout flares, with an emphasis on treat-to-target strategy; the escalation of therapies until the target serum uric acid is reached. Initial treatments include allopurinol and febuxostat, with uricosuric agents, probenecid, sulfinpyrazone and benzbromarone, as adjuncts.